5-(6-((4-Methyl-1-piperazinyl)methyl)-1H-benzimidazol-1-yl)-3-((1R)-1-(2-(trifluoromethyl)phenyl)ethoxy)-2-thiophenecarboxamide
| CAS No. | 929095-18-1 |
|---|---|
| MDL No. | N/A |
| MF | C27H28F3N5O2S |
| MW | 543.60 |
| InChI Key | ZHJGWYRLJUCMRT-QGZVFWFLSA-N |
Pricing & Availability
| Pack Size | Purity | Price | Availability | Action |
|---|---|---|---|---|
| - | - | On Request | On Request | |
| Custom synthesis and bulk supply options are available upon request. | ||||
Product Information
GSK461364 is a benzimidazole with substituents at positions 1 and 6: 5-carbamoyl-4-{(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy}thiophen-2-yl and (4-methylpiperazin-1-yl)methyl, respectively. It is an ATP-competitive PLK1 inhibitor (Ki = 2.2 nM), functioning as an EC 2.7.11.21 polo kinase inhibitor, antineoplastic agent, and apoptosis inducer. It belongs to (trifluoromethyl)benzenes, N-methylpiperazines, benzimidazoles, thiophenes, primary carboxamides, and ethers.
| CAS No. | 929095-18-1 |
|---|---|
| Product Name | 5-(6-((4-Methyl-1-piperazinyl)methyl)-1H-benzimidazol-1-yl)-3-((1R)-1-(2-(trifluoromethyl)phenyl)ethoxy)-2-thiophenecarboxamide |
| Heavy Atom Count | 38 | Rotatable Bond Count | 7 |
| Atom Stereo Count | 1 | Bond Stereo Count | 0 |
| HBA | 7 | HBD | 1 |
| TPSA | 76.620 Ų | Charge | 0 |
| Exact Mass | 543.19158 | Complexity | 1456.69 |
| pKa | 7.130 | XLogP | 5.092 |